Generic diabetes combo drug shows promise in healthy volunteers

NCT ID NCT07372118

Completed Knowledge-focused Sponsor: Humanis Saglık Anonim Sirketi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a generic version of the diabetes medication Synjardy XR (empagliflozin and metformin) works the same as the brand-name drug. Thirty-two healthy adults took a single dose of either the generic or brand tablet under fasting conditions. The goal was to see if the generic releases the same amount of medicine into the bloodstream, which could lead to a more affordable option for people with type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin and Metformin extended-release tablets
What this could lead to: If successful, this study could help bring a lower-cost generic version of Synjardy XR to market for type 2 diabetes patients.
What could go wrong: This is a small, early-phase bioequivalence study in healthy volunteers, not patients. Results may not predict real-world effectiveness or safety in people with diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

Veeda Clinical Research Limited

Ahmedabad, Gujarat, 384205, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.